Potential for trials in Russia "enormous", says ClinStar
Roger Price, director of European business development director at the contract research organisation (CRO) told Outsourcing-pharma that because fewer trials are conducted in the region there is less competition for patients than in the US.
Price also said that the legacy of the USSR's centralised system means that across the region health care provision is focused at key hubs which, he suggested, offers significant benefits in terms of both recruitment and monitoring.
He explained that: “When we do a study we can go to these hospitals, they have databases and we can access those [patients]” and added that developing effective relationships with such institutions is critical to success in the region.
